SEATTLE, June 5, 2023 /PRNewswire/ -- Accolade (Nasdaq: ACCD), the company that provides millions of people and their families with Personalized Healthcare, announced today findings of a new Savanta employer healthcare survey that shows nearly half of employees (49%) are overwhelmed by managing their own and their family members' healthcare and about two-thirds (65%) have delayed or avoided care as a result.
The survey of 2,000 people enrolled in employer-provided healthcare plans, confirmed a direct connection between this strain and delaying care, with the top stressors as cost of care (60%), billing confusion (37%), and difficulty finding a provider and making an appointment (37%). The report also explores barriers to care, including health equity, and an increasing appetite for free and low-cost virtual care among consumers.
"Even with health insurance to help cover the high cost of healthcare, people are feeling stuck when it comes to seeking the care they need. What's concerning is that they are delaying or even avoiding care because of barriers, and that's where Accolade can intervene," said Ryan McQuaid, executive vice president of product and member marketing at Accolade. "By proactively engaging with employees and their families in the moments that matter, we can break the cycle of care delay with a personalized, curated approach that reaches them when they need it most."
Accolade, which delivers healthcare solutions to more than 11 million members insured by their employers, shared its findings through the lens of current healthcare and economic trends, with a focus on four "moments that matter": receiving a new serious diagnosis that requires additional care, managing chronic health conditions, experiencing new symptoms, and finding a provider. More than two-thirds of employees are seeking support from employers in these moments.
Key Findings
Exploring stressors
o The report explores the economic impact of healthcare on employees - data from Kaiser Family Foundation and CNBC that indicates 44% of insured adults worry about covering the health insurance deductible costs, which isn't surprising consider 58% of households are living paycheck to paycheck.
A deeper look at moments that matter
Solutions
Employers impact the healthcare experience of 156 million Americans, and should be empowered to make a positive impact on the health of employees. The report indicates the best ways for them to make an impact:
Accolade's new offering, Accolade Connect, acts on moments that matter most in the healthcare journey to ensure employees understand how and where to get the care they need. It bridges the gap between physical and mental health benefits navigation, advocacy, and care delivery services by integrating three solutions: Personal advocacy, virtual primary care and expert medical opinion. Learn more about Accolade Connect here.
Read more about the report here: https://www.accolade.com/resources/report-employees-delaying-care-at-high-rates/
About Accolade
Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live their healthiest lives. Accolade's employer, health plan and consumer solutions combine virtual primary care and mental health, expert medical opinion and best-in-class care navigation. These offerings are built on a platform that is engineered to care through predictive engagement of population health needs, proactive care that improves outcomes and cost savings, and by addressing barriers to access and continuity of care. Accolade consistently receives consumer satisfaction ratings of over 90%. For more information, visit accolade.com. Follow us on LinkedIn, Twitter, Instagram and Facebook.
Last Trade: | US$6.82 |
Daily Change: | 3.38 98.26 |
Daily Volume: | 36,033,049 |
Market Cap: | US$549.280M |
January 08, 2025 November 13, 2024 October 08, 2024 August 07, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load